Norfloxacin versus trimethoprim-sulfamethoxazole in the therapy of uncomplicated, community-acquired urinary tract infections | Zendy

E. J. C. Goldstein | Zendy; Marc Alpert | Zendy; B P Ginsberg | Zendy

Open Access

Norfloxacin versus trimethoprim-sulfamethoxazole in the therapy of uncomplicated, community-acquired urinary tract infections

Author(s) -

E. J. C. Goldstein,

Marc Alpert,

B P Ginsberg

Publication year - 1985

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.27.3.422

Subject(s) - norfloxacin , proteus mirabilis , trimethoprim , sulfamethoxazole , medicine , enterobacter , urinary system , antibacterial agent , microbiology and biotechnology , proteus , surgery , staphylococcus aureus , antibiotics , escherichia coli , biology , ciprofloxacin , bacteria , biochemistry , genetics , gene

In a prospective, randomized trial, norfloxacin (400 mg perorally, twice a day) was compared with trimethoprim-sulfamethoxazole (160-800 mg perorally, twice a day) in 45 patients with uncomplicated urinary tract infections. Escherichia coli was the most common isolate. Infections due to Enterobacter spp., Proteus mirabilis, Pseudomonas spp., and Staphylococcus spp. were also treated. Norfloxacin was equivalent in effectiveness and safety to trimethoprim-sulfamethoxazole, with a cure rate of 91% at the 5- to 9-day posttherapy visit and 88% at the 4- to 6-week posttherapy visit. It was well tolerated and had a low incidence of side effects.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research